ohm and MGK: If either Bayer or MRK wants to partner on a combo CRC trial with LL, that would be a great development, but if the other suddenly were to succumb to FOMO and also were to make an offer, triggering a bidding war re the terms, CYDY would have markedly increased leverage to obtain much more equitable terms, especially the all important post approval revenue splits and exercisable BO provisions.